Schott Pharma Ag &Amp; Co. Kgaa (1SXP GR) - Friday, Jan 26, 2024

• SCHOTT Pharma AG & Co. KGaA is experiencing accelerating growth in the pharmaceutical packaging industry due to the increasing prevalence of biologics, GLP-1s, and high value solutions.
• The company's HVS segment is driving double-digit revenue growth and is expected to account for a larger percentage of total revenues in the future.
• With solid pricing power in an oligopolistic industry, SCHOTT Pharma is well-positioned to benefit from the success of GLP-1s and further expand its market share.

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.